切除修复交叉互补基因1、乳腺癌易感基因1及微管蛋白β3检测在晚期肺鳞状细胞癌患者GP方案治疗中的指导意义  

Guiding significance of excision repair cross-complement group 1,breast cancer susceptibility gene 1 and tubulin beta 3 detection in GP treatment of patients with advanced lung squamous cell carcinoma

作　　者：李勇平 雷傲利 李文革 李复红 LI Yongping;LEI Aoli;LI Wen'ge;LI Fuhong(Department of Respiratory Medicine,the First Hospital of Weinan,Weinan 714000,Shaanxi,China)

机构地区：[1]渭南市第一医院呼吸内科,陕西渭南714000

出　　处：《癌症进展》2023年第21期2411-2414,共4页Oncology Progress

摘　　要：目的 探讨切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因1(BRCA1)及微管蛋白β3(TUBB3)检测在晚期肺鳞状细胞癌患者吉西他滨+顺铂(GP)方案治疗中的指导意义。方法 选取74例行GP方案治疗的晚期肺鳞状细胞癌患者,采用免疫组化法检测ERCC1、BRCA1及TUBB3表达情况。比较不同临床特征晚期肺鳞状细胞癌患者的ERCC1、BRCA1及TUBB3表达情况。根据免疫组化结果对患者进行分组,3阳性为A组(n=16),2阳性+1阴性为B组(n=18),1阳性+2阴性为C组(n=19),3阴性为D组(n=21),比较4组患者的临床特征、总有效率及疾病控制率。结果 74例晚期肺鳞状细胞癌患者肺鳞状细胞癌组织中ERCC1、BRCA1、TUBB3阳性表达率分别为45.95%、55.41%、47.30%。不同性别、临床分期、分化程度肺鳞状细胞癌患者肺鳞状细胞癌组织中ERCC1、BRCA1及TUBB3阳性表达率比较,差异均有统计学意义(P﹤0.05)。4组患者的性别、年龄、吸烟时间比较,差异均无统计学意义(P﹥0.05);4组患者的临床分期、分化程度比较,差异均有统计学意义(P﹤0.05)。4组患者的总有效率和疾病控制率比较,差异均有统计学意义(P﹤0.01),其中D组患者的总有效率和疾病控制率均最高,A组均最低。结论 ERCC1、BRCA1、TUBB3联合检测能够为GP方案治疗晚期肺鳞状细胞癌提供参考,有助于筛选有效治疗人群,提高GP方案治疗的有效性。Objective To explore the guiding significance of excision repair cross-complement group 1(ERCC1),breast cancer susceptibility gene 1(BRCA1)and tubulin beta 3(TUBB3)detection in gemcitabine+cisplatin(GP)treat-ment of patients with advanced lung squamous cell carcinoma.Method A total of 74 patients with advanced lung squa-mous cell carcinoma who were treated with GP regimen were selected.The expression of ERCC1,BRCA1 and TUBB3 were detected by immunohistochemistry method and were compared in patients with different clinical characteristics.Ac-cording to the immunohistochemical results,the patients were divided into group A(n=16)with 3 positive results,group B(n=18)with 2 positive+1 negative results,group C(n=19)with 1 positive+2 negative results,and group D(n=21)with 3 negative results.The clinical characteristics,total effective rate and disease control rate of the four groups were com-pared.Result The positive expression rates of ERCC1,BRCA1 and TUBB3 in 74 patients with advanced lung squa-mous cell carcinoma were 45.95%,55.41%and 47.30%respectively.There were significant differences for the positive expression rates of ERCC1,BRCA1 and TUBB3 in lung squamous cell carcinoma patients with different gender,clinical stage,and differentiation degree(P<0.05).There were no significant differences for the gender,age and smoking time in the four groups(P>0.05).There were significant differences for the clinical stage and differentiation degree in the four groups(P<0.05).There were significant differences for the total effective rate and disease control rate in the four groups(P<0.01);the total effective rate and disease control rate in group D were the highest,and those in group A were the low-est.Conclusion The combined detection of ERCC1,BRCA1 and TUBB3 can provide reference for the GP treatment of patients with advanced lung squamous cell carcinoma,and is helpful to screen the effective treatment population for the GP regimen,and improve the treatment effect of the GP regimen.

关 键 词：切除修复交叉互补基因1 乳腺癌易感基因1 微管蛋白β3 晚期肺鳞状细胞癌 GP方案 

分 类 号：R734.2[医药卫生—肿瘤]